Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025

Fort Lauderdale, FL, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition II Corp. (the “Company”), a special purpose acquisition company formed as a Cayman Islands exempted company, today announced that commencing December 3, 2025, holders of the units sold in the Company’s initial public offering completed on September 26, 2025, may elect to separately trade the ordinary shares of the Company and the rights included in such units on the Nasdaq Global Market tier of  The Nasdaq Stock Market LLC (“Nasdaq”). Each unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination.